Cargando…

Efficacy of trabectedin in metastatic solitary fibrous tumor

Solitary fibrous tumor is a rare tumor type and has an unpredictable course. Local recurrence rate varies between 9 and 19%, and rate of metastatic involvement between 0 and 36 %. It is characterized by a typical architecture and immuno-histochemistry tests. The most important prognostic factor is t...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaigneau, Loïc, Kalbacher, Elsa, Thiery-Vuillemin, Antoine, Fagnoni-Legat, Christine, Isambert, Nicolas, Aherfi, Lionel, Pauchot, Julien, Delroeux, Delphine, Servagi-Vernat, Stephanie, Mansi, Laura, Pivot, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208416/
https://www.ncbi.nlm.nih.gov/pubmed/22066036
http://dx.doi.org/10.4081/rt.2011.e29
_version_ 1782215612732276736
author Chaigneau, Loïc
Kalbacher, Elsa
Thiery-Vuillemin, Antoine
Fagnoni-Legat, Christine
Isambert, Nicolas
Aherfi, Lionel
Pauchot, Julien
Delroeux, Delphine
Servagi-Vernat, Stephanie
Mansi, Laura
Pivot, Xavier
author_facet Chaigneau, Loïc
Kalbacher, Elsa
Thiery-Vuillemin, Antoine
Fagnoni-Legat, Christine
Isambert, Nicolas
Aherfi, Lionel
Pauchot, Julien
Delroeux, Delphine
Servagi-Vernat, Stephanie
Mansi, Laura
Pivot, Xavier
author_sort Chaigneau, Loïc
collection PubMed
description Solitary fibrous tumor is a rare tumor type and has an unpredictable course. Local recurrence rate varies between 9 and 19%, and rate of metastatic involvement between 0 and 36 %. It is characterized by a typical architecture and immuno-histochemistry tests. The most important prognostic factor is the complete resection of primary tumor. Treatment of recurrences is not clearly established. If a solitary fibrous tumor is too advanced to allow surgical resection, radiotherapy and chemotherapy may be used. The most often used drugs are doxorubicine and\or ifosfamide. We report the case of man with metastatic solitary fibrous tumor treated with trabectedin, administered at a dose of 1.5 mg/m² every 3 weeks. After 3 cycles, metastases had significantly decreased. Recurrence of the disease was demonstrated 8 months after the start of trabectedin. This case shows that trabectedin is a possible treatment option.
format Online
Article
Text
id pubmed-3208416
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher PAGEPress Publications
record_format MEDLINE/PubMed
spelling pubmed-32084162011-11-07 Efficacy of trabectedin in metastatic solitary fibrous tumor Chaigneau, Loïc Kalbacher, Elsa Thiery-Vuillemin, Antoine Fagnoni-Legat, Christine Isambert, Nicolas Aherfi, Lionel Pauchot, Julien Delroeux, Delphine Servagi-Vernat, Stephanie Mansi, Laura Pivot, Xavier Rare Tumors Case Report Solitary fibrous tumor is a rare tumor type and has an unpredictable course. Local recurrence rate varies between 9 and 19%, and rate of metastatic involvement between 0 and 36 %. It is characterized by a typical architecture and immuno-histochemistry tests. The most important prognostic factor is the complete resection of primary tumor. Treatment of recurrences is not clearly established. If a solitary fibrous tumor is too advanced to allow surgical resection, radiotherapy and chemotherapy may be used. The most often used drugs are doxorubicine and\or ifosfamide. We report the case of man with metastatic solitary fibrous tumor treated with trabectedin, administered at a dose of 1.5 mg/m² every 3 weeks. After 3 cycles, metastases had significantly decreased. Recurrence of the disease was demonstrated 8 months after the start of trabectedin. This case shows that trabectedin is a possible treatment option. PAGEPress Publications 2011-07-18 /pmc/articles/PMC3208416/ /pubmed/22066036 http://dx.doi.org/10.4081/rt.2011.e29 Text en ©Copyright L. Chaigneau et al., 2011 This work is licensed under a Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0). Licensee PAGEPress, Italy
spellingShingle Case Report
Chaigneau, Loïc
Kalbacher, Elsa
Thiery-Vuillemin, Antoine
Fagnoni-Legat, Christine
Isambert, Nicolas
Aherfi, Lionel
Pauchot, Julien
Delroeux, Delphine
Servagi-Vernat, Stephanie
Mansi, Laura
Pivot, Xavier
Efficacy of trabectedin in metastatic solitary fibrous tumor
title Efficacy of trabectedin in metastatic solitary fibrous tumor
title_full Efficacy of trabectedin in metastatic solitary fibrous tumor
title_fullStr Efficacy of trabectedin in metastatic solitary fibrous tumor
title_full_unstemmed Efficacy of trabectedin in metastatic solitary fibrous tumor
title_short Efficacy of trabectedin in metastatic solitary fibrous tumor
title_sort efficacy of trabectedin in metastatic solitary fibrous tumor
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208416/
https://www.ncbi.nlm.nih.gov/pubmed/22066036
http://dx.doi.org/10.4081/rt.2011.e29
work_keys_str_mv AT chaigneauloic efficacyoftrabectedininmetastaticsolitaryfibroustumor
AT kalbacherelsa efficacyoftrabectedininmetastaticsolitaryfibroustumor
AT thieryvuilleminantoine efficacyoftrabectedininmetastaticsolitaryfibroustumor
AT fagnonilegatchristine efficacyoftrabectedininmetastaticsolitaryfibroustumor
AT isambertnicolas efficacyoftrabectedininmetastaticsolitaryfibroustumor
AT aherfilionel efficacyoftrabectedininmetastaticsolitaryfibroustumor
AT pauchotjulien efficacyoftrabectedininmetastaticsolitaryfibroustumor
AT delroeuxdelphine efficacyoftrabectedininmetastaticsolitaryfibroustumor
AT servagivernatstephanie efficacyoftrabectedininmetastaticsolitaryfibroustumor
AT mansilaura efficacyoftrabectedininmetastaticsolitaryfibroustumor
AT pivotxavier efficacyoftrabectedininmetastaticsolitaryfibroustumor